Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. Materials and Methods Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL. Results A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS. Conclusion The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.
Abstract
Purpose We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. Materials and Methods Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL. Results A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS. Conclusion The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.
참고문헌 (17)
- Zain JM, "Aggressive T-cell lymphomas : 2021updates on diagnosis, risk stratification and management", Am J Hematol, 96, pp.1027~1046 (2021)
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- Vose J, "International peripheral T-cell and natural killer", T-cell lymphoma study : pathology findings and clinical outcomes, 2008, pp.26, 4124~4130
- Yoon SE, "Comprehensive analysis of peripheral T-cell and natural killer", T-cell lymphoma in Asian patients : a multinational, multicenter, prospective registry study in Asia, 2021, pp.10, 100126~
- Ellin F, "Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas : a study from the Swedish Lymphoma Registry", Blood, 124, pp.1570~1577 (2014)
- Savage KJ, "Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification", Ann Oncol, 15, pp.1467~1475 (2004)
- Park SI, "The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission : report from COMPLETE, a prospective, multicenter cohort study", Cancer, 125, pp.1507~1517 (2019)
- d’Amore F, "Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma : NLG-T-01", J Clin Oncol, 30, pp.3093~3099 (2012)
- Reimer P, "Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas : results of a prospective multicenter study", J Clin Oncol, 27, pp.106~113 (2009)
- Fossard G, "Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction : an analysis of patients from LYSA centers", Ann Oncol, 29, pp.715~723 (2018)
- Cheson BD, "Recommendations for initial evaluation, staging, and respons assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Adams SV, "Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States", J Clin Oncol, 34, pp.963~971 (2016)
- Shi Y, "Current status and progress of lymphoma management in China", Int J Hematol, 107, pp.405~412 (2018)
- Fuji S, "Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival : a retrospective analysis using data from the population-based Osaka Cancer Registry", Ann Hematol, 100, pp.157~165 (2021)
- Advani RH, "Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma : final report from the international T-cell Project", Blood, 138, pp.213~220 (2021)
- Tang T, "Outcomes of patients with peripheral T-cell lymphoma in first complete remission : data from three tertiary Asian cancer centers", Blood Cancer J, 7, pp.653~ (2017)
- Maurer MJ, "Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy", J Clin Oncol, 32, pp.1066~1073 (2014)